It is suggested that these KRAS and GNAS mutations play a critical role in separating the evolution paths leading to pancreatobiliary-type IPMN and further into tubular invasive carcinoma, or intestinal-type IPMN into colloid invasive carcinoma [10]. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.